Latest Advances in Lung Cancer Research

Large trial finds nivolumab after lung cancer surgery didn’t improve survival or prevent recurrence compared to observation alone.

New drug ivonescimab cut death risk 34% in lung cancer trial, outperforming standard immunotherapy plus chemo combination.

Selpercatinib cut lung cancer recurrence risk by 83% in patients with rare RET-positive early-stage non-small cell lung cancer.

New data shows elisrasib provides strong, lasting tumor responses for advanced lung cancer patients, including those who failed previous KRAS-targeted treatments.

New pill sevabertinib (Hyrnuo) shrinks tumors in 70% of patients with rare HER2-mutated lung cancer. Learn about this FDA fast-tracked breakthrough.

A new Phase 3 trial finds Ivonescimab paired with chemotherapy delayed lung cancer progression by 40 % compared to a PD-1 inhibitor combo.

FDA fast-tracks ZL-1310, a promising targeted therapy showing 74% response rate in advanced small cell lung cancer patients with limited treatment options.

AbbVie’s Emrelis, an FDA-approved drug, targets c-Met proteins in NSCLC for effective cancer treatment, marking significant advancements in antibody-drug conjugates (ADCs).

Phase III trial shows mobocertinib performs similarly to chemotherapy for EGFR exon 20 insertion lung cancer patients.

New hope for small cell lung cancer patients as the first patient receives Peluntamig in a clinical trial. This experimental drug targets specific cancer growth pathways.

Final study results show selpercatinib achieves 83% response rate in treatment-naive RET fusion lung cancer patients with durable responses.

Merck halted a lung cancer trial combining vibostolimab with Keytruda due to ineffectiveness and side effects. This setback highlights challenges in developing TIGIT inhibitors for cancer treatment.